The choice between a ritonavir-boosted protease inhibitor- and a non-nucleoside reverse transcriptase inhibitor-based regimen for initiation of antiretroviral treatment – results from an observational study in Germany

Lignende værker

• Ritonavir-Boosted Darunavir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Other Regimens for Initial Antiretroviral Therapy for People with HIV Infection: A Systematic Review
  af: Balayan, Tatevik, et al.
  Udgivet: (2017)
• Unemployment, health, and education of HIV-infected males in Germany
  af: Groß, Mona, et al.
  Udgivet: (2015)
• Analysis of contemporary HIV/AIDS health care costs in Germany: Driving factors and distribution across antiretroviral therapy lines
  af: Treskova, Marina, et al.
  Udgivet: (2016)
• Long-term effectiveness of initiating non-nucleoside reverse transcriptase inhibitor- versus ritonavir-boosted protease inhibitor-based antiretroviral therapy: implications for first-line therapy choice in resource-limited settings
  af: Lima, Viviane D, et al.
  Udgivet: (2016)
• Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens.
  af: Alexandra U Scherrer, et al.
  Udgivet: (2012-01-01)